Klotho Neurosciences, Inc.
0.5162-0.01 (-1.6%)
Oct 29, 4:00:02 PM EDT · NasdaqCM · KLTO · USD
Key Stats
Market Cap
36.31MP/E (TTM)
-Basic EPS (TTM)
-0.46Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Klotho Neurosciences posted a Q2 net loss of $4.1M, up sharply from $0.5M a year ago, driven by $1.9M in operating expenses that quadrupled on higher professional fees, share-based compensation, and initial R&D outlays. Yet financing inflows swelled cash to $8.4M from $64K at year-start, fueled by $11.4M from warrant exercises and $500K each from stock subscriptions and preferred shares. Debt stands at zero after conversions and payoffs. No revenue yet, as the biotech advances its gene therapy platforms. Investors face Nasdaq compliance hurdles.
8-K
KLTO partners for gene therapy manufacturing
Klotho Neurosciences inked a deal on August 6, 2025, with AAVnerGene to manufacture and develop its KLTO-202 gene therapy using the AAVone platform, paying $250,000 upfront plus stage-based fees and a 2% revenue royalty. This partnership leverages AAVnerGene's tech for higher yields, fewer impurities, and faster production over traditional methods, potentially speeding clinical entry while curbing liver-targeting risks via the ATHENA system. Forward-looking statements highlight efficiency gains, yet regulatory hurdles loom large.
8-K
Klotho licenses AAVone platform
Klotho Neurosciences secured an exclusive global license on July 16, 2025, to AAVnerGene's AAVone platform for developing, manufacturing, and commercializing Klotho gene therapies targeting Alzheimer's, Parkinson's, ALS, and aging pathologies. Initial fees start at $250,000 for the first product, scaling to $500,000 for the third, plus 2% royalties on revenues. This partnership promises faster, cheaper production with higher purity and efficacy. Yet regulatory hurdles loom large.
8-K
Regains Nasdaq compliance
Klotho Neurosciences regained Nasdaq compliance on July 14, 2025, meeting the $1.00 minimum bid price and $2.5 million stockholders' equity thresholds. While shifting to the Nasdaq Capital Market from Global, trading persists under KLTO and KLTOW symbols. Compliance holds, but Nasdaq will monitor equity for one year. Delisting looms without cure if it dips.
8-K
FDA grants ALS therapy designation
Klotho Neurosciences secured FDA Orphan Drug Designation for KLTO-202, its gene therapy targeting ALS, on July 10, 2025. This status unlocks tax credits for clinical trials, waives market application fees, and grants seven years of U.S. market exclusivity upon approval. The company eyes proof-of-concept studies in animal models and upcoming FDA/EMA meetings to advance development. Yet regulatory hurdles loom large.
AIBT
Aibotics Inc.
0.00+0.00
ALZN
Alzamend Neuro, Inc.
2.45+0.09
ANRO
Alto Neuroscience, Inc.
14.04+0.42
ANVS
Annovis Bio, Inc.
2.20+0.10
ATHA
Athira Pharma, Inc.
4.08-0.13
IMA
ImageneBio, Inc.
8.79+0.09
KALA
KALA BIO, Inc.
0.80-0.03
KLRS
Kalaris Therapeutics, Inc.
4.87-0.13
KTTA
Pasithea Therapeutics Corp.
0.72-0.01
NGNE
Neurogene Inc.
32.67+1.65